Legend Biotech Corporation reports news on cell therapy development and commercialization, centered on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson. Company updates commonly cover CARVYKTI sales trends, treatment-site expansion, manufacturing capacity, clinical and real-world data from the CARTITUDE program, and label or evidence developments tied to multiple myeloma care.
Legend Biotech news also follows its broader cell therapy pipeline, including allogeneic and in vivo CAR-T programs such as LUCAR-G39D in B-cell non-Hodgkin lymphoma. Recurring announcements include quarterly financial results, scientific-conference presentations, research and manufacturing priorities, advisory input, and corporate governance updates.
Legend Biotech (LEGN) reported third-quarter 2026 net income of $51.7 million, reversing a loss in the comparable prior-year quarter. Revenue rose to $359.5 million from $272.4 million, while operating income reached $46.8 million versus a $43.3 million loss. CARVYKTI net trade sales increased 36% year over year to approximately $710 million.
In CARTITUDE-2 Cohort A, 10 of 20 patients remained alive and progression-free without further anti-myeloma treatment at least five years after one CARVYKTI infusion. The FDA cleared the investigational new drug application for LB2501, supporting a planned U.S. Phase I/II trial in relapsed or refractory B-cell malignancies. Cash, cash equivalents and time deposits totaled approximately $853 million at September 30, 2026. Quarterly operating cash outflow was $35.9 million, versus $28.8 million of inflow a year earlier. Ingrid Zhang became CEO effective September 15, 2026.
Legend Biotech (NASDAQ: LEGN) will present CARVYKTI and investigational cell-therapy findings at ASH in New Orleans on December 12–15, 2026. The program includes two oral presentations, four posters and an ePublication.
In the observational CITADEL study, a preemptive steroid strategy across four U.S. academic centers was associated with 1.6% immune effector cell-associated parkinsonism, versus 2.9% historically. In a CARTITUDE-4 subgroup with lenalidomide- and daratumumab-refractory multiple myeloma, nearly 60% were progression-free 30 months after CARVYKTI infusion; median overall survival was not reached.
Investigational LB2501, designed to generate cancer-targeting immune cells inside patients, produced 100% overall and complete response rates among eight patients at dose level 2, with responses lasting up to five months at cutoff. Updated Phase 1 data for LB2501 and LUCAR-G39D will also be presented.
Legend Biotech (LEGN) will host an investor conference call on November 10, 2026, to review third quarter 2026 financial results. The call and accompanying webcast begin at 8:00 a.m. ET, with senior management providing an overview of quarterly financial performance. A webcast replay and the earnings press release will be available in the website’s Investor Relations section under Events and Presentations approximately two hours after the call concludes.
Legend Biotech (NASDAQ: LEGN) received FDA clearance of its investigational new drug application for LB2501, a CD19/CD20-targeting cell therapy. The clearance supports a planned U.S. Phase 1/2 study in relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. The study will assess safety, tolerability, how the therapy behaves in the body, and preliminary efficacy.
LB2501 is designed to generate cancer-targeting T cells directly inside patients after a single infusion. Legend Biotech says this off-the-shelf approach could avoid several manufacturing steps required for conventional therapies made from a patient's own cells. LB2501 is being evaluated without lymphodepleting chemotherapy, which reduces immune cells before treatment. An ongoing Phase 1 open-label study in China is assessing safety, tolerability, and preliminary efficacy.
Legend Biotech (NASDAQ: LEGN) launched its inaugural ELITE annual grant program for early-career healthcare professionals working on multiple myeloma cell therapy. Applications are open through November 20, 2026. The program offers two categories: Emerging Educator, supporting clinical practice, research, healthcare delivery or education projects; and Emerging Innovator, supporting pilot, expansion or novel approaches specific to multiple myeloma.
An independent steering committee oversees applications. Recipients will be notified in December 2026 and invited to a recognition event in 2027 to present proposals.
Legend Biotech (LEGN) reported five-year CARVYKTI results from 20 patients in CARTITUDE-2 Cohort A on September 25, 2026. At least five years after one infusion, 10 of 20 patients (50%) were alive and progression-free without further anti-myeloma treatment. The five-year overall survival rate was 69.2%. Median progression-free survival was 60.5 months after a median follow-up of 60.7 months; median overall survival was not reached.
The ongoing Phase 2 cohort evaluated patients with relapsed or refractory multiple myeloma after one to three prior lines of therapy. Since an earlier analysis at approximately 30 months of median follow-up, one patient developed acute myeloid leukemia. Two deaths occurred, due to progressive disease and new cancer. No new CAR T-cell-related neurotoxicity was reported during longer follow-up.
Legend Biotech (LEGN) has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, following a Board-led search process.
Zhang succeeds Alan Bash, who has served as Interim CEO since July 2026 and will return to his position as President, CARVYKTI. She most recently served as Chief Commercial Officer for Novartis International, and previously held senior roles at AstraZeneca, Pfizer, and McKinsey & Company, bringing extensive global commercial and operational experience. The Board describes Zhang as the right leader for the company’s next phase of growth and expresses confidence in her ability to advance its cell therapy mission.
Legend Biotech highlights continued execution of its strategic priorities during the leadership transition and reiterates its focus on CARVYKTI, a CAR-T therapy for relapsed or refractory multiple myeloma developed with Johnson & Johnson, and on advancing its broader cell therapy pipeline.
Legend Biotech (LEGN) will present updated long-term and real-world data from its CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) clinical program at the 23rd International Myeloma Society Annual Meeting in Glasgow, Scotland, on September 23-26, 2026.
Key presentations include updated long-term follow-up from the Phase 2 CARTITUDE-2 Cohort A trial in lenalidomide-refractory relapsed or refractory multiple myeloma (RRMM) after 1–3 prior lines of therapy, real-world outcome data from the eMMpower-CART study, and first results from a noninterventional, prospective post-authorization safety study in RRMM. Legend Biotech states that these data further characterize CARVYKTI use across earlier-line and real-world settings.
The release also reiterates extensive safety information for CARVYKTI, including boxed warnings for cytokine release syndrome, neurologic toxicities (including ICANS and parkinsonism), HLH/MAS, prolonged or recurrent cytopenias, immune effector cell-associated enterocolitis, and secondary hematological malignancies, with quantified incidence and timing data from CARTITUDE-1 and -4.
Legend Biotech (NASDAQ: LEGN) announced that interim CEO Alan Bash will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 2:35 p.m. ET. A live webcast and replay will be accessible through the company’s Investor Relations website.
Legend Biotech (NASDAQ: LEGN) reported strong second quarter 2026 results, driven by CARVYKTI® growth and expanding cell therapy programs. CARVYKTI® net trade sales rose 50% year-over-year to approximately $657 million, with availability extended to 348 global sites across 19 markets, including a launch in Ireland.
Total revenue increased to $387.5 million from $255.1 million a year earlier, producing operating income of $57.7 million versus a prior-year loss and net income of $33.2 million versus a $125.4 million loss. Legend Biotech highlighted positive first-in-human data for in vivo CAR-T candidate LB2501 and DLL3-targeted CAR-T LB2102. The company ended June 30, 2026 with about $965 million in cash, cash equivalents and time deposits, supported by net proceeds of roughly $212 million from a 7.7 million ADS offering, and believes this provides runway beyond 2026 as it targets company-wide profit based on adjusted net income.